New Positive Ivermectin Evidence | Dr. John Campbell

Few drugs have been argued about more furiously and understood less clearly than this one. In this report, which is a video analysis rather than a documentary, Dr. John Campbell walks through what he presents as new positive ivermectin evidence, focusing on a study of post exposure dosing. The reported result is specific and narrow. People given a single small oral dose after a known exposure took longer to test positive and recorded more time alive and free of symptoms than those who were not. Campbell sets that alongside laboratory work documenting broad spectrum antiviral activity, and lets viewers weigh it themselves.

What the Study Actually Reports

The distinction that gets lost in almost every public argument about this drug is the difference between treatment and prophylaxis. Most of the large trials that shaped official guidance tested ivermectin as a treatment, given after symptoms had already begun, and measured hospitalization or death as the outcome. The work Campbell reviews here is doing something different. It tests a single dose given shortly after exposure, before infection is established, and measures time to a positive test and symptom free survival time.

Those are softer endpoints than death or intensive care admission, and Campbell does not pretend otherwise. What he argues is that they are meaningful endpoints, that delaying or preventing the establishment of an infection is a legitimate clinical goal, and that a study designed around prevention cannot be dismissed by pointing at trials designed around late treatment. The new positive ivermectin evidence in this report is a claim about timing as much as about the molecule.

The Antiviral Case in the Laboratory

The interest in this compound was never arbitrary. Ivermectin has been used against parasitic disease for decades, with a very large safety record at approved doses, and the discovery of the avermectin class was recognized with a Nobel Prize in 2015. Separately, multiple in vitro infection models have documented antiviral activity against a range of viruses, which is the broad spectrum property Campbell cites. Cell culture work published early in the pandemic showed inhibition of SARS-CoV-2 replication.

That laboratory signal is real and it is why serious researchers pursued the question. It is also where the strongest objection lives.

The Dose Problem

The concentrations that suppressed the virus in cell culture were far higher than the plasma concentrations a person reaches on standard oral dosing. Critics have argued from the start that the gap is wide enough to make the in vitro result clinically irrelevant, and that closing it would require doses outside the established safety range. Proponents counter that the drug concentrates in lung tissue rather than distributing evenly through plasma, and that plasma measurement understates exposure where it matters. This argument has not been settled by direct tissue measurement in infected humans, which is why it keeps recurring.

Why the Large Trials Reached a Different Conclusion

The mainstream position rests on the big randomized controlled trials. TOGETHER in Brazil, ACTIV-6 in the United States and PRINCIPLE in the United Kingdom each enrolled large numbers of outpatients and each failed to find a clinically meaningful benefit on their primary endpoints. On that basis the FDA, the EMA and the World Health Organization do not recommend ivermectin for COVID outside of clinical trials.

The credibility problem was compounded from the other direction. Several early meta analyses that showed dramatic benefit drew heavily on studies later retracted or shown to contain fabricated data, and when those studies were removed the pooled effect shrank sharply. That history is a genuine reason for caution and it should be part of any honest account of the evidence.

Advocates reply that none of the large trials tested the post exposure prophylaxis question at the doses and timing that the positive studies used, and that a null result for one protocol is not a null result for every protocol. That reply is logically sound. Whether the remaining positive signal is large enough to matter is exactly what remains unresolved.

What This Report Is Good For

Nothing here is medical advice, and Campbell does not offer any. What the report provides is a clear look at how a single question splinters into several once you specify dose, timing and endpoint. Viewers who arrive convinced the drug is either a miracle or a hoax will find that neither position survives the details intact.

The wider lesson is about how quickly a scientific question can become a tribal marker. Once that happened with this compound, positive findings were dismissed without reading and negative findings were dismissed without reading, and the actual work of specifying what was tested on whom stopped getting done in public. Watching new positive ivermectin evidence examined slowly, with the study on screen, is a useful corrective regardless of where you land.

This report was featured in the March 2026 Monthly Report under Health Watch. Browse the full MUST WATCH Documentary Library for more on medicine, evidence and health freedom.